Home | Publications | Diagnostics place holder
place holder place holder

Diagnostics

Diagnostics & Pathology Laboratories


Publication Date   April 2008
Publisher   Cygnus
Product Type   Report
Pages   51
ISBN Number   not applicable
Product Code   CYG082
Ask a question about this product?

Price £600.00

approximately: $1,059 | €761

Summary


Increasing health consciousness and preventive care have changed the landscape of healthcare services market in more ways than one. Whether it is wellness checkups, preventive care checkups or insurance-related checkups, diagnostics and pathology laboratories are growing significantly, fuelled by the growth in outsourcing diagnostics tests and clinical research. Diagnostics and pathology lab test services market in India holds 44% of the medical devices and diagnostics market, valued at INR125.87 billion in 2007.According to Cygnus estimates, Indian diagnostic and pathological labs test services market is valued at INR55.9 billion (2007) and is estimated to reach INR139 billion by 2012.

Scope of the Report

In this innovative report, it covers basic trends in diagnostic & pathology industry. A brief market overview of diagnostic and healthcare market is been analysed including global, Indian market scenario and major markets.

  • The report analyses the facts regarding the accreditions & quality control aspects in diagnostics and pathology market.
  • It presents the growth drivers for healthcare industry with reference thealthcare institutes and services.
  • It provides issues & challenges involved in healthcare industry.
  • It provides information on the critical success factors with reference tautomation & standardization, Laboratory accreditation etc.
  • 6 Major players and have been profiled providing introduction, financial, operational, business strategy & competitive advantages, infrastructure accreditations of the company.
  • The report provides a future outlook of diagnostic & pathology market.

Content


  • Executive Summary
  • Highlights
  • 1. Industry & Market Overview
    • 1.1 Global medical and diagnostics laboratory12
    • 1.2 Indian healthcare industry
      • 1.2.2 Healthcare infrastructure
      • 1.2.3 Overview of diagnostics & pathology laboratory Industry
        • 1.2.3.1 Industry structure15
        • 1.2.3.2 Industry classification
        • 1.2.3.3 Therapeutic segments
      • 1.3.4 Existing Business Models
  • 2. Accreditations & Quality Control
  • 2.1introduction19
    • 2.2 National Accreditation Board for Testing & Calibration Laboratories
    • 2.3 College for American Pathologist
      • 2.3.1 Benefits of CAP Accreditation
    • 2.4 Effect of the accreditation process among the clinical labs
      • 2.4.1 Quality manual
      • 2.4.2 Quality System Procedure
      • 2.4.3 Standard Test Operating Procedure (SOP)
      • 2.4.4 Records
      • 2.4.5. Quality control (Interlab/external)
      • 2.4.6. Internal audit
      • 2.4.7. Overall cost/expenses for Audit
  • 3. Major Players
    • 3.1 Introduction
    • 3.2 Metropolis
      • 3.2.1. Company Background
      • 3.2.2. Contact Address
      • 3.2.3 Management Team
      • 3.2.4. Infrastructure & Accreditations
        • 3.2.4.1 Infrastructure
        • 3.2.4.2 Accreditations
      • 3.2.5. Business Strategy & Competitive Advantages
        • 3.2.5.1 Strategies
        • 3.2.5.2 Competitive Advantages
      • 3.2.6. Outlook
    • 3.3 SRL Ranbaxy
      • 3.3.1. Company Background
      • 3.3.2. Contact Address
      • 3.3.3. Management Team
      • 3.3.4. Infrastructure & Accreditations
        • 3.3.4.1 Infrastructure
        • 3.3.4.2 Accreditations
      • 3.3.5. Business Strategy & Competitive Advantages
        • 3.3.5.1 Strategies
        • 3.3.5.2 Competitive Advantages
      • 3.3.6. Outlook
    • 3.4 Wellspring
      • 3.4.1. Company Background
      • 3.4.2. Contact Address:
      • 3.4.3. Management Team
      • 3.4.4. Infrastructure & Accreditations
        • 3.4.4.1 Infrastructure
        • 3.4.4.2 Accreditations
      • 3.4.5. Business Strategy & Competitive Advantages
        • 3.4.5.1 Strategies
        • 3.4.5.2 Competitive Advantages
      • 3.4.6. Outlook
    • 3.5 Dr Lal PathLabs
      • 3.5.1. Company Background
      • 3.5.2. Contact Address
      • 3.5.3. Management Team
      • 3.5.4. Infrastructure & Accreditations
        • 3.5.4.1 Infrastructure
        • 3.5.4.2 Accreditations
      • 3.5.5. Business Strategy & Competitive Advantages
        • 3.5.5.1 Strategies
        • 3.5.5.2 Competitive Advantages
      • 3.5.6. Outlook
    • 3.6 Thyrocare
      • 3.6.1. Company Background
      • 3.6.2. Contact Address
      • 3.6.3. Management Team
      • 3.6.4. Infrastructure & Accreditations
        • 3.6.4.1 Infrastructure
        • 3.6.4.2 Accreditations
      • 3.6.5. Business Strategy & Competitive Advantages
        • 3.6.5.1 Strategies
        • 3.6.5.2 Competitive Advantages
      • 3.6.6. Outlook
    • 3.7 Anand Labs
      • 3.7.1. Company Background
      • 3.7.2. Contact Address
      • 3.7.3. Management Team
      • 3.7.4. Infrastructure & Accreditations
        • 3.7.4.1 Infrastructure
        • 3.7.4.2 Accreditations
      • 3.7.5. Business Strategy & Competitive Advantages
        • 3.7.5.1 Strategies
        • 3.7.5.2 Competitive Advantages
      • 3.7.6. Outlook
  • 4. Growth Drivers
    • 4.1 Introduction
    • 4.2 Healthcare Institutes
      • 4.2.1 Foreign hospitals outsourcing diagnostics tests
      • 4.2.2 Polyclinics
      • 4.2.3 Pharmacies
      • 5.2.4 Medical KPO
    • 4.3 Healthcare Services
      • 4.3.1 CRO
      • 4.3.2 Molecular diagnostics
      • 4.3.3 Pharmacogenomics
    • 4.4 Theranostics, driving diagnostic test in drug development
    • 4.5 Logistics and Infrastructure
    • 4.6 IT Infrastructure and Network
    • 4.7 Insurance
  • 5. Critical Success Factors
    • 5.1 Automation and standardisation
    • 5.2 Success of tests
    • 5.3 Processing blood samples
    • 5.4 Laboratory accreditation
  • 6. Issues and Challenges
    • 6.1 Regulatory issues
    • 6.2 Reimbursement pressures
    • 6.3 Analytical and quality issues
    • 6.4 Accreditation procurement
  • 7. Future Outlook
  • Annexure I
  • Annexure Ii